Rheumatoid arthritis (RA) is an autoimmune disorder characterized by inflammation and
bone erosion. The exact mechanism of RA is still unknown, but various immune cytokines …

Two new pathways, T cell receptor signaling and a hematopoietic-specific signal
transduction pathway, have been discovered that allow future pharmacologic interventions …

Objective: To determine whether rheumatoid factor (RF), anti-cyclic citrullinated peptide
(CCP) antibodies, or carriage of shared epitope (SE) and PTPN22 genetic susceptibility …

As indicators of responsiveness to a tumour necrosis factor (TNF) α blocking agent
(infliximab) are lacking in rheumatoid arthritis, we have used gene profiling in peripheral …

Introduction About 30% of rheumatoid arthritis patients fail to respond adequately to TNFα-
blocking therapy. There is a medical and socioeconomic need to identify molecular markers …

Objective. To determine whether there is a quantitative relationship between smoking history
and response to therapy with tumor necrosis factor (TNF) antagonists. Methods. A history of …

Rheumatoid arthritis (RA) is a chronic, disabling disease of the synovial joints, thought to be
autoimmune in origin. The emergence of biologic therapies has proven to be highly …

Rheumatoid arthritis (RA), a chronic inflammatory autoimmune disorder, is characterised by
persistent synovial inflammation, erosion of bones and cartilage, leading to joint destruction …

Rheumatoid arthritis (RA) is a heterogeneous autoimmune disorder of unknown cause with
variable clinical expression. About 70% of patients are women. Genetic factors play an …

Pharmacogenetic studies have traditionally focused on genes involved in processes that
affect the pharmacokinetics of small-molecule drugs, such as drug metabolism. However …